Biocon Biologics believes in harnessing the power of strategic partnerships and collaborations to pursue the kind of innovation needed to attain the dream of ensuring equitable healthcare services worldwide. While we have developed in-house R&D strengths to deliver cutting-edge science, we have also built strategic global partnerships of a symbiotic nature that allow us to share risks, lower costs, maximize our efficiencies, expedite development and expand our reach.
This collaborative approach has helped us expand access to essential medicines globally.
Our long-standing and successful global partnership with Viatris to co-develop a range of biosimilar antibodies and insulin analogs started in 2009, bringing in complementary skills and experience while allowing us to share then risks and rewards. This collaboration led us to combine our advanced R&D strengths and robust manufacturing capabilities in biosimilars with our partner’s regulatory and commercialization expertise in developed markets to together achieve many ‘firsts’ and set new global benchmarks.
Biocon Biologics’ acquisition of the global biosimilars business of Viatris brings together the two companies’ teams, which have been collaborating on common projects, into a single, integrated organization driven by a common vision and mission.
We partnered with Sandoz, a division of Novartis, in 2018 for the development of next-generation biosimilars portfolio for immunology and oncology. This synergistic, global partnership with Sandoz prepares us for the next wave of biosimilar opportunities that are opening up. This partnership is structured on an equal economic share with Biocon Biologics having increased rights in developed markets and exclusive rights in most emerging markets. The responsibility for development, manufacturing and ownership of the marketing authorizations is shared between the partners.
Serum Institute Life Sciences
Vaccines and antibodies for infectious disease are a natural adjacency to Biocon Biologics’ existing capabilities in biologics for non-communicable diseases. The strong synergies between our existing capabilities and the evolving demand for biologics or vaccines against infectious diseases led Biocon Biologics to enter a strategic alliance with Serum Institute Life Sciences (SILS) for vaccines and infectious disease antibodies in September 2021.
The ‘asset-light’ deal structure of this alliance with the world’s largest vaccine maker has ensured that Biocon Biologics has access to assured vaccine manufacturing capacity for the next 15 years.
Biocon Biologics will have global commercialization rights for SILS’ vaccine portfolio, including COVID-19 vaccines. Beyond the COVID-19 vaccines portfolio, the partnership provides access to SILS’ current development pipeline to address unmet needs in the areas of infectious and vector-borne diseases.
Biocon Biologics partnered with U.S.-based Adagio Therapeutics in July 2021 for an exclusive license to manufacture and commercialize ADG20 in India and select emerging markets. ADG20 is a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses.
Biocon Biologics has expanded its commercial footprint globally through a hybrid model, wherein it has a direct commercial presence in some countries and leverages regional partners in others.